Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
“While we’re disappointed in this outcome, we believe we have strong
arguments supporting the validity of our patent and intend to appeal the
decision as we work to create additional intellectual property
protecting CTP-543,” stated
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about the strength of
Concert's intellectual property, and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the right to request for
reconsideration after a written decision is issued and other factors
discussed in the "Risk Factors" section of our most recent Annual Report
on Form 10-K filed with the Securities and Exchange Commission and in
other filings that we make with the
Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
Kathryn Morris (media)
The Yates Network